Atossa shareholders approve reverse stock split up to 20:1, re-elect directors

ATOSSA THERAPEUTICS, INC.

Reverse stock split amendment approved: 2,336,815 for, 1,866,873 against, 33,271 abstentions.
Three Class II directors re-elected: Galli, Steinhart, Cigler; broker non-votes ~2.2M each.
Ratification of Ernst & Young as auditor for FY 2026 passed: 3.7M for, 370K against, 151K abstentions.
Advisory vote on executive compensation approved: 1.53M for, 444K against, 2.22M broker non-votes.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

ATOSSA THERAPEUTICS, INC. shareholders approved Approval of Amendment to the Amended and Restated Certificate of Incorporation to Effect a Reverse Stock Split of the Common Stock, if Deemed Necessary or Appropriate by the Board at the 2026-05-07 meeting.

Proposal: reverse split
Outcome: passed
Meeting: 2026-05-07

Exact text from the filing

The stockholders approved an amendment to the Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio from 2:1 to 20:1, inclusive, if determined necessary or appropriate by the Board, by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 2,336,815 1,866,873 33,271 0

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

ATOSSA THERAPEUTICS, INC. shareholders approved Election of three Class II directors at the 2026-05-07 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-05-07

Exact text from the filing

The stockholders elected the three Class II directors by the following votes: Nominee Votes For Votes Withheld Broker Non-Votes • Stephen J. Galli, M.D. 1,726,410 288,389 2,222,160 • Richard I. Steinhart 1,730,171 284,628 2,222,160 • Tessa Cigler, M.D., M.P.H. 1,750,694 264,105 2,222,160

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

ATOSSA THERAPEUTICS, INC. shareholders approved Advisory Vote on Executive Compensation at the 2026-05-07 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2026-05-07

Exact text from the filing

The stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 1,530,390 444,616 39,793 2,222,160

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

ATOSSA THERAPEUTICS, INC. shareholders approved Ratification of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-05-07 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-05-07

Exact text from the filing

The stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 3,714,889 370,496 151,574 0

View on SEC.gov

Browse all shareholder votes →

ATOSSA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-213373

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.